Skip to main content
Case reports of anifrolumab use in 2 pts w/ chronic, scarring discoid lupus unresponsive to steriods, HCQ, immunosuppres

Dr. John Cush RheumNow

3 years 6 months ago
Case reports of anifrolumab use in 2 pts w/ chronic, scarring discoid lupus unresponsive to steriods, HCQ, immunosuppressants & CTX. Case 1 SLEDAI from 13 to 2 in 24 weeks & CLASI-A from 26 to 3 in 20wks. Cs 2 CLASI-A decr 24 to 5 after 1 infusion https://t.co/JE3PVyskm4
Older Lupus Patients Need Follow-Up After Hospital Discharge

Medicare beneficiaries 65 and older with lupus faced dram

Dr. John Cush RheumNow

3 years 6 months ago
Older Lupus Patients Need Follow-Up After Hospital Discharge Medicare beneficiaries 65 and older with lupus faced dramatically higher mortality when they received no follow-up care during the month after a hospital stay, researchers found. https://t.co/4mFctXGQH9 https://t.co/2Q1z03myud
It's time to play, know your numbers! You know that famous game we play almost every other week, every other year.

htt

Dr. John Cush RheumNow

3 years 6 months ago
It's time to play, know your numbers! You know that famous game we play almost every other week, every other year. https://t.co/JgCJzSuzHZ https://t.co/oiyB8vCOuD
Researchers at NYU College of Dentistry have developed a single score to describe the level of cytokines in the saliva, and this score is linked with the severity of clinical gum inflammation, according to a study published in the journal PLOS ONE. 
A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD). Assays for cytokines (serum IFN-α or selected IFN-induced cytokines) were performed by nanoString, ELISA or Simoa. Patients were followed for 2 years for the diagnosis of a new onset SARD. 
Study of 232 pediatric #SLE pts. Over 12 mos 47% achieved LLDAS & Damage seen in 40% after 6.2 yrs F/U. Getting t

Dr. John Cush RheumNow

3 years 6 months ago
Study of 232 pediatric #SLE pts. Over 12 mos 47% achieved LLDAS & Damage seen in 40% after 6.2 yrs F/U. Getting to LLDAS w/in 12 mos is assoc w less damage. LLDAS w/in 12 mos more likely in Absence of renal involvement. https://t.co/pGethJCw4e https://t.co/eYpVueIKbf
Rheums: Treating #RA, Do you Consider/Use RA Rx guidelines?

Dr. John Cush RheumNow

3 years 6 months ago
Rheums: Treating #RA, Do you Consider/Use RA Rx guidelines?
On Dec. 19, 2022, the U.S. Food & Drug Administration (FDA) approved subcutaneous abaloparatide (Tymlos) for the tre

Dr. John Cush RheumNow

3 years 6 months ago
On Dec. 19, 2022, the U.S. Food & Drug Administration (FDA) approved subcutaneous abaloparatide (Tymlos) for the treatment of men with osteoporosis at high risk of fracture https://t.co/igwxVCdKuo https://t.co/COSmDrsv4p
Alternatives to Vagal nerve stimulation Dr Eric Ruderman #RWCS23 @RWCSmtg https://t.co/zpJsh10LLQ

Dr. John Cush RheumNow

3 years 6 months ago
Alternatives to Vagal nerve stimulation Dr Eric Ruderman #RWCS23 @RWCSmtg https://t.co/zpJsh10LLQ
2nd study results with Implantable Vagal nerve stim in active #RA pts. Dr Eric Ruderman #RWCS23 https://t.co/S6aFSVjePD

Dr. John Cush RheumNow

3 years 6 months ago
2nd study results with Implantable Vagal nerve stim in active #RA pts. Dr Eric Ruderman #RWCS23 https://t.co/S6aFSVjePD
Implantable Vagal nerve stimulation studied in 17 active #RA pts DAS ~6. Dr Eric Ruderman #RWCS23 https://t.co/Xn9Ur199n

Dr. John Cush RheumNow

3 years 6 months ago
Implantable Vagal nerve stimulation studied in 17 active #RA pts DAS ~6. Dr Eric Ruderman #RWCS23 https://t.co/Xn9Ur199nv
Dr Eric Ruderman #RWCS23
Bee Venom around since 1859, vaguely better than placebo https://t.co/3Xl7SZwQPm

Dr. John Cush RheumNow

3 years 6 months ago
Dr Eric Ruderman #RWCS23 Bee Venom around since 1859, vaguely better than placebo https://t.co/3Xl7SZwQPm
RT @uptoTate: ADA biosimilars: one is out now and seven due out by July. “It’s time to get onboard with biosimilarsâ

Dr. Rachel Tate uptoTate

3 years 6 months ago
ADA biosimilars: one is out now and seven due out by July. “It’s time to get onboard with biosimilars” @RheumNow @RWCSmtg #RWCS23
RT @uptoTate: Do you use TNFi in pregnant patients? @RheumNow #RWCS23 @RWCSmtg

Dr. Rachel Tate uptoTate

3 years 6 months ago
Do you use TNFi in pregnant patients? @RheumNow #RWCS23 @RWCSmtg
RT @uptoTate: Low dose prednisolone in RA. GLORIA shows toxicity can be a real issue. @RWCSmtg @RheumNow #RWCS23 https:/

Dr. Rachel Tate uptoTate

3 years 6 months ago
Low dose prednisolone in RA. GLORIA shows toxicity can be a real issue. @RWCSmtg @RheumNow #RWCS23 https://t.co/KstyKdjWn2
×